[go: up one dir, main page]

WO2008153150A1 - Method for culturing cell population containing nk cells and use of the cell population - Google Patents

Method for culturing cell population containing nk cells and use of the cell population Download PDF

Info

Publication number
WO2008153150A1
WO2008153150A1 PCT/JP2008/060900 JP2008060900W WO2008153150A1 WO 2008153150 A1 WO2008153150 A1 WO 2008153150A1 JP 2008060900 W JP2008060900 W JP 2008060900W WO 2008153150 A1 WO2008153150 A1 WO 2008153150A1
Authority
WO
WIPO (PCT)
Prior art keywords
cells
cell population
monoclonal antibody
therapeutic agent
effect
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/060900
Other languages
French (fr)
Japanese (ja)
Inventor
Shiho Sato
Hidemasa Jinguji
Atsutaka Noguchi
Masato Muto
Takamichi Izumi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medinet Co Ltd
Original Assignee
Medinet Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medinet Co Ltd filed Critical Medinet Co Ltd
Publication of WO2008153150A1 publication Critical patent/WO2008153150A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4205—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/49—Breast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

It is intended to provide a method for efficiently proliferating and activating a cell population containing a high percentage of NK cells and γδT cells. Further, it is also intended to provide a pharmaceutical and a therapeutic method in which the cell population and a monoclonal antibody therapeutic agent are used in combination for enhancing an effect of the monoclonal antibody therapeutic agent via ADCC. By adding glucocorticoid and IL-18 to peripheral blood mononuclear cells after initiation of culture, NK cells and γδT cells can be selectively proliferated, and a cell population containing a large amount of NK cells and γδT cells with a high growth rate can be obtained. The obtained cell population has an excellent cytotoxic activity and cell preservation stability. Further, the ratio of CD16-positive cells is high, therefore, an effect of enhancing ADCC is high. Accordingly, the NK cells can increase a therapeutic effect of a monoclonal antibody therapeutic agent via ADCC.
PCT/JP2008/060900 2007-06-15 2008-06-13 Method for culturing cell population containing nk cells and use of the cell population Ceased WO2008153150A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007-159578 2007-06-15
JP2007159578A JP2010220479A (en) 2007-06-15 2007-06-15 Method for culturing NK cells and use of NK cells

Publications (1)

Publication Number Publication Date
WO2008153150A1 true WO2008153150A1 (en) 2008-12-18

Family

ID=40129753

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/060900 Ceased WO2008153150A1 (en) 2007-06-15 2008-06-13 Method for culturing cell population containing nk cells and use of the cell population

Country Status (2)

Country Link
JP (1) JP2010220479A (en)
WO (1) WO2008153150A1 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012176796A1 (en) * 2011-06-24 2012-12-27 国立大学法人九州大学 Method for amplifying nk cells
JP2013006793A (en) * 2011-06-24 2013-01-10 Tella Inc Composition and method for amplifying nk cell
CN111748524A (en) * 2020-05-08 2020-10-09 嘉禾弘生(深圳)健康产业集团有限公司 A method for efficient expansion of NK cells in vitro by factor method
CN112912494A (en) * 2018-07-26 2021-06-04 耶稣圣婴儿童医院 Therapeutic formulations of gamma-delta T cells and natural killer cells and methods of making and using them
CN113398262A (en) * 2021-06-18 2021-09-17 北京康爱瑞浩生物科技股份有限公司 Composition for treating HER2 positive gastric cancer and application
EP4230728A4 (en) * 2020-09-15 2024-11-20 Shin, Ji-Seop Immune cell proliferation/activation kit and immune cell culture method using same proliferation/activation kit

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016209021A1 (en) * 2015-06-24 2016-12-29 주식회사 차바이오텍 Method for proliferating natural killer cells and composition for proliferating natural killer cells
KR101909879B1 (en) * 2015-06-24 2018-10-19 주식회사 차바이오텍 Method and Composition for Proliferating of Natural Killer Cell
JP6073417B2 (en) * 2015-06-26 2017-02-01 チャ バイオテック カンパニー リミテッド Spontaneous killing cell proliferation method and composition for spontaneous killing cell proliferation
WO2020043670A1 (en) * 2018-08-27 2020-03-05 Affimed Gmbh Cryopreserved nk cells preloaded with an antibody construct
FR3112939B1 (en) * 2020-07-31 2024-01-05 Univ Montpellier Universal cell therapy product and its use

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BOWLES J.A. ET AL.: "CD16 polymorphisms and NK activation induced by monoclonal antibody-coated target cells", J. IMMUNOL. METHODS, vol. 304, no. 1-2, 2005, pages 88 - 99, XP005065140 *
HASHIMOTO W. ET AL.: "Interleukin-18(IL-18) ni yoru Natural Killer(NK) Saibo Kasseika Oyobi Shuyo Saibo no Apoptosis Yudo", TOKEIBU SYUYO, vol. 29, no. 1, 25 March 2003 (2003-03-25), pages 217 - 223 *
HASHIMOTO W. ET AL.: "Interleukin-18(IL-18) ni yoru Natural Killer(NK) Saibo Kasseika Oyobi Shuyo Saibo no Apoptosis Yudo; Tokeibu Shuyo Chiryo eno Oyo", TOHOKU UNIVERSITY DENTAL JOURNAL, vol. 22, no. 2, 30 December 2003 (2003-12-30), pages 124 - 125 *
ISHIDA T. ET AL.: "Gan Men'eki no Shin Tenkai Kotai Ryoho no Saranaru Tenkai", GEKKAN MEDICAL SCIENCE DIGEST, vol. 30, no. 4, 25 April 2004 (2004-04-25), pages 138 - 142 *
KITAMURA M. ET AL.: "Bunshi Hyoteki Chiryoyaku -Atarashii Gan Chiryoyaku-", JIBIINKOKA TENBO, vol. 47, no. 6, 15 December 2004 (2004-12-15), pages 455 - 459 *
YOSHITAKE Y. ET AL.: "Gan Men'eki Ryoho Kenkyu no Shin Tenkai", JAPANESE JOURNAL OF CLINICAL MEDICINE, vol. 63, no. 4, 28 April 2005 (2005-04-28), pages 46 - 55 *

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012176796A1 (en) * 2011-06-24 2012-12-27 国立大学法人九州大学 Method for amplifying nk cells
JP2013006793A (en) * 2011-06-24 2013-01-10 Tella Inc Composition and method for amplifying nk cell
JP2013027385A (en) * 2011-06-24 2013-02-07 Kyushu Univ Method for amplifying nk cells
CN103620022A (en) * 2011-06-24 2014-03-05 国立大学法人九州大学 Method for amplifying nk cells
CN103620022B (en) * 2011-06-24 2015-09-30 国立大学法人九州大学 The amplification method of NK cell
US9404083B2 (en) 2011-06-24 2016-08-02 Kyushu University, National University Corporation Method for amplifying NK cells
JP2021532829A (en) * 2018-07-26 2021-12-02 オスペダーレ ペディアトリコ バンビーノ ジェズ Therapeutic preparations and methods of manufacture and use of gamma-delta T cells and natural killer cells
CN112912494A (en) * 2018-07-26 2021-06-04 耶稣圣婴儿童医院 Therapeutic formulations of gamma-delta T cells and natural killer cells and methods of making and using them
JP7565271B2 (en) 2018-07-26 2024-10-10 オスペダーレ ペディアトリコ バンビーノ ジェズ Therapeutic preparations of gamma-delta T cells and natural killer cells and methods of making and using
JP2025011150A (en) * 2018-07-26 2025-01-23 オスペダーレ ペディアトリコ バンビーノ ジェズ Therapeutic preparations of gamma-delta T cells and natural killer cells and methods of making and using
CN111748524A (en) * 2020-05-08 2020-10-09 嘉禾弘生(深圳)健康产业集团有限公司 A method for efficient expansion of NK cells in vitro by factor method
EP4230728A4 (en) * 2020-09-15 2024-11-20 Shin, Ji-Seop Immune cell proliferation/activation kit and immune cell culture method using same proliferation/activation kit
CN113398262A (en) * 2021-06-18 2021-09-17 北京康爱瑞浩生物科技股份有限公司 Composition for treating HER2 positive gastric cancer and application

Also Published As

Publication number Publication date
JP2010220479A (en) 2010-10-07

Similar Documents

Publication Publication Date Title
WO2008153150A1 (en) Method for culturing cell population containing nk cells and use of the cell population
WO2012021632A3 (en) Generation and use of pluripotent stem cells
WO2008118392A3 (en) Synthetic cell platforms and methods of use thereof
NZ593364A (en) Pharmaceutical preparation comprising supernatant of blood mononuclear cell culture
AU2012274478A8 (en) Method for amplifying NK cells
WO2008136398A1 (en) Cell culture method using amino acid-enriched medium
EP2410043A3 (en) Stem cells culture systems
EP4372081A3 (en) Making and using in vitro-synthesized ssrna for introducing into mammalian cells to induce a biological or biochemical effect
UA106925C2 (en) Probiotic compositions and the device for their introduction
MX2009004238A (en) Methods and compositions for treatment of bone defects with placental cell populations.
NZ593365A (en) Pharmaceutical preparation comprising a blood mononuclear cell culture
WO2008006895A3 (en) Methods and compositions for increasing the efficiency of therapeutic antibodies using gamma delta t cell activators
WO2011082038A3 (en) Improved reprogramming compositions
JP2015061520A5 (en)
EP4324913A3 (en) Culture media for stem cells
PH12014501175A1 (en) Medium composition for rejuvenating stem cells
WO2009145419A9 (en) Composition comprising vegetable peptone for promoting stem cell proliferation
WO2008056368A3 (en) Use of ex-vivo cultured hematopoietic cells for treatment of peripheral vascular diseases
WO2012131733A3 (en) Media compositions for enriching cultures of stem cells
JP2012143229A5 (en)
WO2021250583A3 (en) 3d culture of mesenchymal lineage precursor or stem cells
MX2013006838A (en) Effervescent compositions and uses thereof.
WO2007136760A3 (en) Method of growth of mesenchymal cells under non-adherent conditions for clinical applications
WO2012118349A3 (en) Differentiation and proliferation method for natural killer cells from cd14-positive monocytes
WO2010013906A3 (en) Method for separating highly active stem cells from human stem cells and highly active stem cells separated thereby

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08777211

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08777211

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP